Key statistics dashboard for Cerus Corporation (CERS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
Stock Data
| Price | $2.53 |
| Market Cap | $510M |
| Beta | 1.63 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -69.06 |
| Price / Book | 7.16 |
| P/S | 2.27 |
| P/FCF | -275.46 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 52.05% |
| EBIT Margin | 0.55% |
| EBITDA Margin | 1.31% |
| Operating Margin | -0.73% |
| Net Margin | -3.06% |
Financial Health
| Current Ratio | 1.83 |
| Quick Ratio | 1.07 |
| Cash Ratio | 0.21 |
| Debt / Equity | 1.10 |
| Debt / Assets | 37.43% |
| Interest Coverage | -0.21 |
Per-Share Data
| Revenue per share | 1.10 |
| Book Value per share | 0.35 |
| Cash per share | 0.28 |
| FCF per share | -0.01 |
| Tangible Book Value per share | 0.35 |
| Dividend per share | 0.00 |
Related companies: CVRX · MASS · NPCE · QTRX · RXST · SENS · SGHT
Explore sector: Healthcare · Medical - Devices
More sections of CERS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks